TABLE 2.

Sensitivities of NAATs for detection of N. gonorrhoeae and C. trachomatis with self-collected glans swab specimens from asymptomatic and symptomatic MSM^a

Collection method and specimen	Test	Sensitivity (%)
		N. gonorrhoeae		C. trachomatis
		Asymptomatic MSM	Symptomatic MSMb	Asymptomatic MSM	Symptomatic MSM
Method 1c
Glans swab	SDA	100 (7/7)d	91.8 (67/73)e	55.6 (5/9)	56.5 (13/23)f
Glans swab	AC2	100 (7/7)	95.9 (70/73)	66.7 (6/9)	56.5 (13/23)f
FCU	AC2	71.4 (5/7)	100 (73/73)	77.8 (7/9)	100 (23/23)
Method 2g
Glans swab	SDA	42.9 (3/7)	85.7 (18/21)	53.8 (7/13)	66.7 (10/15)
Glans swab	AC2	42.9 (3/7)	95.2 (20/21)	84.6 (11/13)	53.3 (8/15)
FCU	AC2	85.7 (6/7)	100 (21/21)	76.9 (10/13)	86.7 (13/15)

^aTrue-positive results are defined as a positive result by AC2 with FCU, positive results for glans swab specimens by both NAATs, or a positive result by a single NAAT with glans swab specimens confirmed by an alternate amplification method. Overall, the prevalence rates of C. trachomatis infection were 3.7% (22/602) for asymptomatic MSM and 13.6% (38/280) for symptomatic MSM. Overall, the prevalence rates of N. gonorrhoeae were 2.3% (14/602) for asymptomatic MSM and 33.6% (94/280) for symptomatic MSM.

^bUrethral symptoms only.

^cFor specimen collection by method 1, the prevalence rates of N. gonorrhoeae and C. trachomatis among asymptomatic MSM were 2.5 (7/279) and 3.2 (9/279), respectively, and those among symptomatic MSM were 34.3 (73/213) and 10.8 (23/213), respectively.

^dThe values in parentheses are the number of MSM positive/total number of MSM tested.

^eP = 0.04 by comparison with the results of AC2 with FCU.

^fP < 0.001 by comparison with the results of AC2 with FCU.

^gFor specimen collection by method 2, the prevalence rates of N. gonorrhoeae and C. trachomatis among asymptomatic MSM were 2.2 (7/323) and 4.0 (13/323), respectively, and those among symptomatic MSM were 31.3 (21/67) and 22.4 (15/67), respectively.